The mutational status in driver genes such as epidermal growth factor receptor (EGFR) mutations, Kirsten rat sarcoma viral oncogene (KRAS) mutations, or anaplastic lymphoma kinase (ALK) translocations or mutations could drive the prognosis for stage III unresectable NSCLC treated by chemoradiotherapy [6,7,8,9,10]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.